Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruud Delwel

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
Haematologica|October 29, 2013
The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitorsAdam Liss, Chia-Huey Ooi, Polina Zjablovskaja, et al.
Cell Stem Cell|July 6, 2013
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformationSu Jung Song, Keisuke Ito, Ugo Ala, et al.
Blood|September 12, 2022
EVI1 drives leukemogenesis through aberrant ERG activationJohannes Schmoellerl, Inês A M Barbosa, Martina Minnich, et al.
Molecular and Cellular Biology|July 1, 2005
Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion proteinGenyan Yang, Waleed Khalaf, Louis van de Locht, et al.
Blood|November 9, 2014
Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathwaysStefan Gröschel, Mathijs A Sanders, Remco Hoogenboezem, et al.
Cancer Cell|November 14, 2006
Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemiaKaren Keeshan, Yiping He, Bas J Wouters, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trialsNazik Rayman, King H Lam, Bronno van der Holt, et al.
Blood|August 20, 2005
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significanceRoel G W Verhaak, Chantal S Goudswaard, Wim van Putten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemiaArati V Rao, Peter J M Valk, Klaus H Metzeler, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|April 15, 2003
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AMLSahar Barjesteh van Waalwijk van Doorn-Khosrovani, Claudia Erpelinck, Joost Meijer, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
Haematologica|October 29, 2013
The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitorsAdam Liss, Chia-Huey Ooi, Polina Zjablovskaja, et al.
Cell Stem Cell|July 6, 2013
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformationSu Jung Song, Keisuke Ito, Ugo Ala, et al.
Blood|September 12, 2022
EVI1 drives leukemogenesis through aberrant ERG activationJohannes Schmoellerl, Inês A M Barbosa, Martina Minnich, et al.
Molecular and Cellular Biology|July 1, 2005
Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion proteinGenyan Yang, Waleed Khalaf, Louis van de Locht, et al.
Blood|November 9, 2014
Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathwaysStefan Gröschel, Mathijs A Sanders, Remco Hoogenboezem, et al.
Cancer Cell|November 14, 2006
Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemiaKaren Keeshan, Yiping He, Bas J Wouters, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trialsNazik Rayman, King H Lam, Bronno van der Holt, et al.
Blood|August 20, 2005
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significanceRoel G W Verhaak, Chantal S Goudswaard, Wim van Putten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemiaArati V Rao, Peter J M Valk, Klaus H Metzeler, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|April 15, 2003
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AMLSahar Barjesteh van Waalwijk van Doorn-Khosrovani, Claudia Erpelinck, Joost Meijer, et al.
Pageof 14